{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:29:24Z","timestamp":1760142564779,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.biopha.2010.12.016","type":"journal-article","created":{"date-parts":[[2011,6,25]],"date-time":"2011-06-25T05:06:51Z","timestamp":1308978411000},"page":"569-577","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["An experimental approach to studying the effectiveness and safety of meglumine antimoniate formulations"],"prefix":"10.1016","volume":"65","author":[{"given":"G.","family":"Delgado","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Plaza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mari\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Granados","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2010.12.016_bib0005","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0738-081X(96)00036-3","article-title":"Natural history, clinical evolution, and the host-parasite interaction in New World cutaneous Leishmaniasis","volume":"14","author":"Weigle","year":"1996","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.biopha.2010.12.016_bib0010","first-page":"7","article-title":"Leishmaniasis: a public health challenge that demands concerted effort and will (editorial)","volume":"1","author":"Saravia","year":"2006","journal-title":"Biomedica"},{"key":"10.1016\/j.biopha.2010.12.016_bib0015","doi-asserted-by":"crossref","first-page":"145","DOI":"10.7705\/biomedica.v26i1.1508","article-title":"Geographic distribution of Leishmania species isolated from patients at the National Institute of Dermatology Federico Lleras Acosta E.S.E., 1995\u20132005","volume":"26","author":"Ovalle","year":"2006","journal-title":"Biomedica"},{"key":"10.1016\/j.biopha.2010.12.016_bib0020","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4103\/0022-3859.928","article-title":"Cutaneous leishmaniasis: an overview","volume":"49","author":"Hepburn","year":"2003","journal-title":"J Postgraduate Med"},{"key":"10.1016\/j.biopha.2010.12.016_bib0025","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11259-005-0059-4","article-title":"Pancreatitis associated with N-methyl-glucamine therapy in a dog with leishmaniasis","volume":"29","author":"Aste","year":"2005","journal-title":"Vet Res Commun"},{"key":"10.1016\/j.biopha.2010.12.016_bib0030","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.rvsc.2006.10.008","article-title":"Evaluation of renal and hepatic functions in dogs naturally infected by visceral leishmaniasis submitted to treatment with meglumine antimoniate","volume":"83","author":"Ikeda-Garcia","year":"2007","journal-title":"Res Vet Sci"},{"key":"10.1016\/j.biopha.2010.12.016_bib0035","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1590\/S0037-86822005000300011","article-title":"A fatal case of mucocutaneous leishmaniasis after pentavalent antimonial use","volume":"38","author":"Oliveira","year":"2005","journal-title":"Rev Soc Bras Med Trop"},{"issue":"2","key":"10.1016\/j.biopha.2010.12.016_bib0040","first-page":"165","article-title":"Muertes asociadas al uso de antimoniales pentavalentes en el tratamiento de leishmaniosis cutanea en Colombia: reporte de serie de casos","volume":"27","author":"Velez","year":"2007","journal-title":"Biomedica"},{"key":"10.1016\/j.biopha.2010.12.016_bib0045","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1128\/AAC.45.3.913-916.2001","article-title":"Glutathione-induced conversion of pentavalent antimony to trivalent antimony in meglumine antimoniate","volume":"45","author":"Frezard","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.biopha.2010.12.016_bib0050","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1111\/j.1365-3156.2007.01962.x","article-title":"Short communication: the cost-effectiveness of cutaneous leishmaniasis patient management during an epidemic in Chaparral, Colombia in 2004","volume":"12","author":"Vega","year":"2007","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.biopha.2010.12.016_bib0055","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.etp.2006.03.009","article-title":"Regulatory aspects of immunotoxicology","volume":"57","author":"Schulte","year":"2006","journal-title":"Exp Toxicol Pathol"},{"key":"10.1016\/j.biopha.2010.12.016_bib0060","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.etp.2006.03.013","article-title":"The ICH\u00a0S8 immunotoxicity guidance. Immune function assessment and toxicological pathology: autonomous or synergistic methods to predict immunotoxicity?","volume":"57","author":"Spanhaak","year":"2006","journal-title":"Exp Toxicol Pathol"},{"key":"10.1016\/j.biopha.2010.12.016_bib0065","first-page":"50","article-title":"Desarrollo y validaci\u00f3n de un m\u00e9todo de determinaci\u00f3n por espectrofotometr\u00eda visible de antimoniato de meglumina en inyectables","volume":"36","author":"Rojas","year":"2008","journal-title":"Rev Col Cienc Qu\u00edm Farm"},{"key":"10.1016\/j.biopha.2010.12.016_bib0070","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2307\/3281866","article-title":"Activity of antileishmanial agents against amastigotes in human monocyte-derived macrophages and in mouse peritoneal macrophages","volume":"70","author":"Berman","year":"1984","journal-title":"J Parasitol"},{"key":"10.1016\/j.biopha.2010.12.016_bib0075","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1006\/phrs.2001.0825","article-title":"Flow cytometry, a useful tool for detecting the lethal effect of pentamidine on leishmania viannia complex promastigote forms","volume":"44","author":"Delgado","year":"2001","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.biopha.2010.12.016_bib0080","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4269\/ajtmh.2005.72.421","article-title":"Short report: efficacy of pentavalent antimony for treatment of colombian cutaneous leishmaniasis","volume":"72","author":"Soto","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.biopha.2010.12.016_bib0085","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/15476910701680087","article-title":"Characterizing the effect of pentamidine isethionate on the immune system using mouse splenocytes as an experimental model","volume":"4","author":"Plaza","year":"2007","journal-title":"J Immunotoxicol"},{"key":"10.1016\/j.biopha.2010.12.016_bib0090","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1432-1033.1995.tb20583.x","article-title":"Trypanothione reductase from Leishmania donovani. Purification, characterisation and inhibition by trivalent antimonials","volume":"230","author":"Cunningham","year":"1995","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.biopha.2010.12.016_bib0095","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.etp.2006.03.012","article-title":"Design and evaluation of immunotoxicity studies","volume":"57","author":"Roth","year":"2006","journal-title":"Exp Toxicol Pathol"},{"key":"10.1016\/j.biopha.2010.12.016_bib0100","first-page":"44","article-title":"Cuantificaci\u00f3n por citometr\u00eda de flujo de esplenocitos CD4+, CD8+, CD19+y CD14+ obtenidos de cuatro especies murinas empleadas en estudios de inmunotoxicolog\u00eda","volume":"36","author":"Salguero","year":"2007","journal-title":"Rev Col Cienc Qu\u00edm Farm"},{"issue":"Suppl. 1","key":"10.1016\/j.biopha.2010.12.016_bib0105","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.trstmh.2006.02.022","article-title":"Treatment of New World cutaneous leishmaniasis with miltefosine","volume":"100","author":"Soto","year":"2006","journal-title":"Trans R Soc Trop Med Hyg"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332211000448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332211000448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:49:40Z","timestamp":1760093380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332211000448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0753332211000448"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2010.12.016","relation":{},"ISSN":["0753-3322"],"issn-type":[{"type":"print","value":"0753-3322"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An experimental approach to studying the effectiveness and safety of meglumine antimoniate formulations","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2010.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}